JP2005525336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525336A5 JP2005525336A5 JP2003567394A JP2003567394A JP2005525336A5 JP 2005525336 A5 JP2005525336 A5 JP 2005525336A5 JP 2003567394 A JP2003567394 A JP 2003567394A JP 2003567394 A JP2003567394 A JP 2003567394A JP 2005525336 A5 JP2005525336 A5 JP 2005525336A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- inhibitor
- prevention
- group
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 229940127218 antiplatelet drug Drugs 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000008212 P-Selectin Human genes 0.000 claims 1
- 108010035766 P-Selectin Proteins 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical group CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 claims 1
- 229950008393 cariporide Drugs 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960005202 streptokinase Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10206358A DE10206358A1 (de) | 2002-02-14 | 2002-02-14 | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Behandlung von thrombotischer und inflammatorischer Erkrankungen |
| PCT/EP2003/001020 WO2003068212A1 (de) | 2002-02-14 | 2003-02-03 | Verwendung von inhibitoren des natrium-wasserstoff-austauschers zur behandlung von thrombotischer und inflammatorischer erkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525336A JP2005525336A (ja) | 2005-08-25 |
| JP2005525336A5 true JP2005525336A5 (de) | 2006-03-16 |
Family
ID=27634998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003567394A Abandoned JP2005525336A (ja) | 2002-02-14 | 2003-02-03 | 血栓性および炎症性障害の治療のためのナトリウム／水素交換体の阻害剤の使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1480628A1 (de) |
| JP (1) | JP2005525336A (de) |
| AR (1) | AR038502A1 (de) |
| AU (1) | AU2003208368A1 (de) |
| BR (1) | BR0307618A (de) |
| CA (1) | CA2476446A1 (de) |
| DE (1) | DE10206358A1 (de) |
| MX (1) | MXPA04007387A (de) |
| TW (1) | TW200403988A (de) |
| WO (1) | WO2003068212A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10305070A1 (de) * | 2003-02-07 | 2004-08-26 | Merck Patent Gmbh | Verwendung von N-(4,5-Methansulfonyl-2-methyl-benzoyl)-guanidin |
| AU2009243749B2 (en) * | 2008-05-09 | 2013-11-21 | Merck Patent Gmbh | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627193A (en) * | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
| DE19734693A1 (de) * | 1997-08-11 | 1998-01-22 | Hoechst Marion Roussel De Gmbh | Verwendung von Cariporide als Inhibitor des zellulären NA+/H+-Exchangers (NHE) zur Herstellung eines Medikaments zur Behandlung von cardialen und nichtcardialen Krankheiten |
-
2002
- 2002-02-14 DE DE10206358A patent/DE10206358A1/de not_active Withdrawn
-
2003
- 2003-02-03 WO PCT/EP2003/001020 patent/WO2003068212A1/de not_active Application Discontinuation
- 2003-02-03 BR BR0307618-0A patent/BR0307618A/pt not_active IP Right Cessation
- 2003-02-03 CA CA002476446A patent/CA2476446A1/en not_active Abandoned
- 2003-02-03 MX MXPA04007387A patent/MXPA04007387A/es not_active Application Discontinuation
- 2003-02-03 JP JP2003567394A patent/JP2005525336A/ja not_active Abandoned
- 2003-02-03 AU AU2003208368A patent/AU2003208368A1/en not_active Abandoned
- 2003-02-03 EP EP03706415A patent/EP1480628A1/de not_active Withdrawn
- 2003-02-12 AR ARP030100448A patent/AR038502A1/es not_active Application Discontinuation
- 2003-02-12 TW TW092102811A patent/TW200403988A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weitz et al. | New anticoagulants | |
| Torholm et al. | Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study | |
| Gorog et al. | Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) | |
| Ozier et al. | Pharmacological agents: antifibrinolytics and desmopressin | |
| Jiménez et al. | Apixaban: an oral direct factor-xa inhibitor | |
| RU2125450C1 (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина | |
| Christiansen et al. | Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II | |
| JP2006524203A (ja) | トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 | |
| JP2005525336A5 (de) | ||
| JPS61112018A (ja) | 線溶増強剤 | |
| US20030199457A1 (en) | Prevention and treatment of thromboembolic disorders associated with arterial & venous thrombosis | |
| Chakrabarti et al. | Advances in antithrombotic agents | |
| JP2005525338A5 (de) | ||
| RU2004136583A (ru) | Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов | |
| KR20110110582A (ko) | 혈소판 응집억제용 또는 혈전용해용 의약 조성물 | |
| Roe et al. | Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. | |
| Kishimoto et al. | M118–A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes | |
| Langevitz et al. | Scleroderma hypertensive renal crisis and the changing pattern of mortality in systemic sclerosis (scleroderma) | |
| Mattia et al. | Respiratory depression following iatrogenic tramadol overuse in a patient with chronic renal failure | |
| BOLTON | Disseminated intravascular coagulation | |
| Jay et al. | How anticoagulants work | |
| Hamrah et al. | An Overview of Anticoagulants | |
| PT1343523E (pt) | Utilização do factor de coagulação vii activado para o tratamento de grandes hemorragias induzidas por terapia trombolítica | |
| Turpie | Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art | |
| Turpie | Oral Direct Factor Xa Inhibitors |